These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

443 related articles for article (PubMed ID: 31053339)

  • 1. Frequency, characteristics and nature of risk factors associated with use of QT interval prolonging medications and related drug-drug interactions in a cohort of psychiatry patients.
    Das B; Rawat VS; Ramasubbu SK; Kumar B
    Therapie; 2019 Dec; 74(6):599-609. PubMed ID: 31053339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Leading 20 drug-drug interactions, polypharmacy, and analysis of the nature of risk factors due to QT interval prolonging drug use and potentially inappropriate psychotropic use in elderly psychiatry outpatients.
    Das B; Ramasubbu SK; Agnihotri A; Kumar B; Rawat VS
    Ther Adv Cardiovasc Dis; 2021; 15():17539447211058892. PubMed ID: 34841978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Top 20 drug - drug interactions, polypharmacy and analysis of the nature of risk factors due to QT interval prolonging drug use in elderly psychiatry outpatients.
    Das B; Ramasubbu SK; Kumar B; Rawat VS
    J Family Med Prim Care; 2020 Dec; 9(12):6023-6040. PubMed ID: 33681037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of QT interval prolonging drug-drug interactions (QT-DDIs) in psychiatry wards of tertiary care hospitals in Pakistan: a multicenter cross-sectional study.
    Khan Q; Ismail M; Haider I; Khan F
    Int J Clin Pharm; 2017 Dec; 39(6):1256-1264. PubMed ID: 28895028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence of the risk factors for QT prolongation and associated drug-drug interactions in a cohort of medical inpatients.
    Khan Q; Ismail M; Haider I; Ali Z
    J Formos Med Assoc; 2019 Jan; 118(1 Pt 1):109-115. PubMed ID: 29458991
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency, characteristics and risk factors of QT interval prolonging drugs and drug-drug interactions in cancer patients: a multicenter study.
    Khan Q; Ismail M; Khan S
    BMC Pharmacol Toxicol; 2017 Dec; 18(1):75. PubMed ID: 29191244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients.
    Hefner G; Hahn M; Hiemke C; Toto S; Wolff J; Roll SC; Klimke A
    J Neural Transm (Vienna); 2021 Feb; 128(2):243-252. PubMed ID: 33417009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. QTc Prolongation Associated With Psychiatric Medications: A Retrospective Cross-Sectional Study of Adult Inpatients.
    Shao W; Ayub S; Drutel R; Heise WC; Gerkin R
    J Clin Psychopharmacol; 2019; 39(1):72-77. PubMed ID: 30531476
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prescribing Practices of QT Interval Prolonging Drugs in Critically Ill Older Adults in South India.
    Moolambally SR; Malik A; Boloor A A
    Kathmandu Univ Med J (KUMJ); 2023; 21(83):298-303. PubMed ID: 39206650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reckless administration of QT interval-prolonging agents in elderly patients with drug-induced torsade de pointes.
    Jackobson G; Carmel NN; Lotan D; Kremer A; Justo D
    Z Gerontol Geriatr; 2018 Jan; 51(1):41-47. PubMed ID: 27878411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. QT Prolongation, Torsades de Pointes, and Psychotropic Medications: A 5-Year Update.
    Beach SR; Celano CM; Sugrue AM; Adams C; Ackerman MJ; Noseworthy PA; Huffman JC
    Psychosomatics; 2018; 59(2):105-122. PubMed ID: 29275963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of the risk factors for QT interval prolongation and associated drug-drug interactions in coronary care units.
    Khan Q; Ismail M; Haider I
    Postgrad Med; 2018 Nov; 130(8):660-665. PubMed ID: 30145917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence, Attributes, and Risk Factors of QT-Interval-Prolonging Drugs and Potential Drug-Drug Interactions in Cancer Patients: A Prospective Study in a Tertiary Care Hospital.
    Agnihotri A; Ramasubbu SK; Bandyopadhyay A; Bidarolli M; Nath UK; Das B
    Cureus; 2024 May; 16(5):e60492. PubMed ID: 38882995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of QT interval prolongation in patients admitted to cardiac care units and frequency of subsequent administration of QT interval-prolonging drugs: a prospective, observational study in a large urban academic medical center in the US.
    Tisdale JE; Wroblewski HA; Overholser BR; Kingery JR; Trujillo TN; Kovacs RJ
    Drug Saf; 2012 Jun; 35(6):459-70. PubMed ID: 22612851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.
    Vandael E; Marynissen T; Reyntens J; Spriet I; Vandenberghe J; Willems R; Foulon V
    Int J Clin Pharm; 2014 Aug; 36(4):757-65. PubMed ID: 24805801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High prevalence of risk factors in elderly patients using drugs associated with acquired torsades de pointes chronically in Colombia.
    Moreno-Gutiérrez PA; Gaviria-Mendoza A; Cañón MM; Machado-Alba JE
    Br J Clin Pharmacol; 2016 Aug; 82(2):504-11. PubMed ID: 27060989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of Medication Associated with QTc Prolongation Used Among Critically Ill Patients.
    Al-Azayzih A; Al-Qerem W; Al-Azzam S; Muflih S; Al-Husein BA; Kharaba Z; Kanaan RJ; Rahhal D
    Vasc Health Risk Manag; 2024; 20():27-37. PubMed ID: 38318252
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Drug-drug interactions with risk of QT-prolongation. A epidemiological study in Belgian community pharmacies].
    Vandael E; De WuLf I; Foulon V
    J Pharm Belg; 2016 Dec; (4):14-23. PubMed ID: 30281244
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone, QTc interval prolongation, and torsade de pointes: a systematic review of case reports.
    Vieweg WV; Hasnain M; Hancox JC; Baranchuk A; Digby GC; Kogut C; Crouse EL; Koneru JN; Deshmukh A; Pandurangi AK
    Psychopharmacology (Berl); 2013 Aug; 228(4):515-24. PubMed ID: 23812796
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of QTc interval prolongation and its associated risk factors among psychiatric patients: a prospective observational study.
    Ali Z; Ismail M; Nazar Z; Khan F; Khan Q; Noor S
    BMC Psychiatry; 2020 Jun; 20(1):277. PubMed ID: 32493330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.